Epix launches new MS-325 trial

MR contrast developer Epix Medical has launched a multicenter trial evaluating its MS-325 blood pool contrast agent for high-resolution vessel imaging.

The goal of the study is to optimize high-resolution imaging with MS-325 as the first step in the characterization of vascular wall structures and vulnerable plaque, according to the Cambridge, MA-based firm.

By AuntMinnie.com staff writers
July 8, 2004

Related Reading

Schering submits MS-325 for EU approval, June 7, 2004

Epix raises $96 million, June 4, 2004

Epix floats new debt, June 2, 2004

Schering gets Swedish approval for Primovist, April 5, 2004

Schering gets European OK for Zevalin for NHL, January 22, 2004

Copyright © 2004 AuntMinnie.com

Page 1 of 606
Next Page